Arcturus’ stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial
In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market…